NeurAxis (NRXS) Q3 2026 earnings review
NeurAxis wins major insurers, but executive tax payments drain cash
NeurAxis, a maker of ear-worn nerve stimulation devices for severe stomach pain, broke a nine-month logjam in insurance coverage while burning throughnearly half its cash. Revenue rose 150% from a year ago to $2.0 million and gross margin reached 86.6% as more patients billed through insurance instead of a discounted assistance program. However, cash dropped to $4.5 million after the company paid employee tax bills on a stock-option swap, prompting chief executive Brian Carrico to raise $1.7 million through fourth-quarter share sales.
| Revenue | $2.03M +150% from a year ago (+5% from Q2) |
|---|---|
| Gross margin | 86.6% +3.3 percentage points from a year ago |
| Covered lives | 147M up from ~101M in the first half |
| Cash on hand | $4.5M down from $8.3M in June (+$1.7M raised in Q4) |
⚖️ Verdict: 🟢 Bullish
The story got better because major national insurers issued written coverage policies, lifting covered lives from about 101 million to 147 million after three quarters of no movement. That expansion gives hospitals the insurance backing they need to order regularly. The bad news: sales grew only 5% from the second quarter while hiring lifted regular overhead costs by 46% from a year ago, and the executive tax payout forced immediate shareholder dilution.
The question now is how quickly those 46 million newly covered lives turn into hospital orders. Either the enlarged insurance pool pushes clinics past their coverage thresholds and speeds up quarterly sales growth, or hospital billing delays keep sequential growth slow while new commercial hires widen the cash burn. First-half 2027 revenue and cash burn will settle it.
🐂 Bull Case
New Insurer Wins Break Three-Quarter Coverage Stall
NeurAxis sells IB-Stim, a small device placed behind the ear that sends gentle electrical pulses to relieve severe stomach pain in children. For three straight quarters, insurance coverage for the treatment sat near 100 million people. That pause raised the risk that hospital orders would level off once the device maker finished selling into its first group of approved states.
Multiple national health insurers issued written coverage policies this quarter, lifting the covered pool to 147 million people. By our math, NeurAxis added about 46 million covered lives in three months, nearly triple its reach from a year ago. The wins came after a permanent billing code took effect in January and pediatric medical guidelines named the therapy as the only recommended device for irritable bowel pain.
This expansion matters because children's hospitals usually wait until about 70% of their local patients have insurance coverage before ordering regularly. Adding 46 million lives should push more clinics past that mark, though new policies typically take three to four months to turn into orders.
What to watch: covered lives and quarterly revenue growth in the first half of 2027. If the new policies push hospitals over the coverage threshold, sequential sales growth will speed up once the four-month setup lag passes.
Full-Price Reimbursements Lift Gross Margin and Prices
Before insurers covered IB-Stim, the medical technology group supplied many devices through a financial assistance program at steep discounts. When gross margin dipped slightly from 86.4% in the first quarter to 85.9% in the second, it looked as if the boost from switching patients to full-price insurance billing had already run its course.
Third-quarter results proved the pricing gain still has room to run. Gross margin rose 3.3 percentage points from a year ago to 86.6%, beating the first-quarter high, while cost of goods sold fell from 16.7% of sales to 13.4%. Unit deliveries rose 92% and revenue jumped 150%, which means average selling prices climbed about 30% from a year ago by our math.
What to watch: the exact average selling price per device on the conference call or in the quarterly filing. A figure above $1,000 would confirm that newer insurance policies are lifting prices beyond the second quarter's $992 level.
New Commercial Leaders Back Up Coverage Gains
Winning an insurance policy does not automatically bring in orders, because doctors and hospital billing teams need help navigating insurer paperwork. NeurAxis also holds a Federal Supply Schedule contract, an agreement that lets it sell directly to Veterans Affairs medical centers serving 7 million patients.
To turn those approvals into device orders, chief executive Brian Carrico launched a commercial expansion, "including the hiring of a Chief Commercial Officer and a Vice President of Market Access". Putting a full-time market access leader on staff brings insurer negotiations in-house and supports clinic billing teams across newly covered states.
What to watch: an update on the ten independent sales representatives planned for the Veterans Affairs channel. Confirming they are trained and selling in the field would show the federal contract is ready to bring in orders.
🐻 Bear Case
Executive Tax Bill Drains Cash and Forces Share Sales
Carrico said that "disciplined balance sheet management remains a priority" and stressed a focus on capital efficiency. Yet an executive compensation swap approved this summer took a heavy toll on the bank account and forced the Carmel, Indiana company to sell more shares.
Cash fell from $8.3 million in June to $4.5 million in September. The $3.8 million drop happened "primarily due to the payment of employee withholding taxes related to the net settlement of restricted stock units issued upon the cancelation of stock options", NeurAxis said. The swap also triggered a $4.3 million one-time stock compensation charge, pushing general and administrative overhead up from 232.0% of revenue to 347.4%.
- Cash balance on September 30: $4.5 million, down $3.8 million in three months
- One-time stock compensation charge: $4.3 million in administrative overhead
- Fourth-quarter share sales: $1.7 million raised through its at-the-market stock facility
Paying employee tax bills in cash from a small balance sheet speeds up shareholder dilution. Even after raising $1.7 million in the fourth quarter to bring pro forma cash to $6.2 million by our math, the company will likely need more funding before sales cover expenses.
What to watch: quarterly operating cash burn in the third-quarter filing. A regular burn above $1.5 million per quarter would leave roughly one year of cash on hand even after the recent share sales.
Quarter-to-Quarter Sales Growth Slows Before New Costs Hit
"Our sales team has gained momentum from the increase of insurance coverage and we are expecting that trend to accelerate as we secure the last large insurers in the very near future," Carrico said. While revenue jumped 150% from a weak $0.81 million quarter a year ago, progress from the second quarter was much smaller.
Sales rose 5.1% from the second quarter's $1.93 million to $2.03 million, slowing from a 20.0% quarterly jump in the spring by our math. At the same time, administrative and overhead costs excluding the $4.3 million one-time stock charge rose 45.8% from a year ago to $2.75 million on recruiting fees and new hires. Excluding one-offs, the operating loss widened 8.5% to $2.28 million.
What to watch: fourth-quarter sequential revenue growth. Because new hires take three to four months to generate hospital orders, another quarter of single-digit sequential sales growth would widen cash losses.
Risks this quarter didn't answer
The earnings release did not include the operating metrics or channel details needed to check three standing concerns.
- Account metrics: the release omitted ordering hospital counts, prior-authorization approval rates, and exact average selling prices; the conference call will show whether clinic adoption broadened.
- Hospital capacity and concentration: no update on whether sales remain concentrated in the top 10 to 20 children's hospitals or how fast clinics are clearing committee and Medicaid billing delays.
- Clinical trial and pipeline dates: no mention of the post-operative pain study, the second-generation IB-Stim device, or revenue from the rectal expulsion testing device.
💲 Other KPIs
Selling costs rose 31.3% from a year ago as higher device sales triggered larger commission payouts. Because revenue more than doubled over the same period, selling expenses fell from 94.0% of sales a year ago to 49.4% this quarter by our math, showing that existing territories are covering more of their direct sales costs.
Spending on clinical studies more than doubled, rising 120.7% from $0.13 million a year ago and ticking up from $0.27 million last quarter. The neuromodulation device maker started new trials to win Food and Drug Administration clearances for additional conditions, including adult studies that insurers require before covering adult patients.
🔮 Guidance
Unchanged. Chief executive Brian Carrico expects to sign the remaining major national health insurers in the very near future, matching his earlier target of late 2026 or early 2027. After adding about 46 million covered lives this quarter to reach 147 million, the company needs another 53 million lives over the next five quarters to meet Carrico's goal of passing 200 million by the end of 2027.
❓ Key Questions
How many hospitals ordered devices in the third quarter?
NeurAxis previously tracked active ordering accounts and insurance approval rates, then switched to year-to-date totals in the second quarter and omitted them from this release. Standalone third-quarter figures will show whether growth came from new hospitals or existing clinics.
Are the ten Veterans Affairs sales reps in the field?
Leadership planned to have ten commission-only representatives trained and selling to Veterans Affairs hospitals by September 15. Investors need to know how many reps are active and how much revenue the federal contract contributed this quarter.
What was the exact cash tax bill for executive stock?
Cash dropped by $3.8 million in the quarter, driven by employee tax withholdings on canceled stock options. Disclosing the exact tax payment separates the one-time payout from ongoing quarterly operating cash burn.
What share of devices still ship at discounted prices?
Gross margin reached 86.6% as more orders billed through insurance rather than the discounted financial assistance program. Knowing the remaining share of discounted units shows how much pricing upside is left before new insurer policies take effect.